12:00 AM
Aug 20, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Reolysin: Completed Phase I enrollment

Oncolytics completed enrollment of 36 patients in the open-label, dose-escalation U.K. Phase I REO 012 trial evaluating IV Reolysin in combination with...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >